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ABSTRACT 
Primary biliary cirrhosis (PBC) is characterized by progressive non-suppurative destruction of 
small bile ducts resulting in intrahepatic cholestasis, fibrosis and ultimately end-stage liver 
disease. Timely intervention with ursodeoxycholic acid is associated with excellent survival; 
although approximately one-third of all patients fail to achieve biochemical response, signifying 
a critical need for additional therapeutic strategies. Obeticholic acid (OCA) is a potent ligand of 
the nuclear hormone receptor farnesoid X receptor (FXR). Activation of FXR inhibits bile acid 
synthesis and protects against toxic accumulation in models of cholestasis and facilitates hepatic 
regeneration in pre-clinical studies. Data from recent phase II and phase III controlled trials 
suggests a therapeutic impact of OCA in PBC biochemical non-responders, as evidenced by 
change in proven laboratory surrogates of long-term outcome. Dose-dependent pruritus is a 
common adverse effect, but may be overcome through dose-titration. Longer-term studies are 
needed with focus on safety and long-term clinical efficacy. 
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 3
Introduction  
Primary biliary cirrhosis (PBC) is an immune-mediated hepatobiliary disorder characterised by 
ductopenia, chronic cholestasis and progressive liver fibrosis [1–4]. Although there are multiple 
animal models proposed, often with similar immunological abnormalities as patients with PBC, 
therapeutic efforts have thus far been based entirely on human clinical trials [5–9]. Presently, the 
mainstay of treatment is ursodeoxycholic acid (UDCA), which in addition to stimulating 
hepatobiliary secretions is a potent intracellular signaling molecule, inducing choleresis through 
mitogen-activated protein kinase (MAPK) and integrin-dependent mechanisms [10]; as well as 
protecting epithelia from ‘toxic’ effects of low pH bile acids [11]. Survival advantage is 
demonstrated best for UDCA-treated patients with early-stage PBC receiving timely and 
appropriately dosed therapy (13 – 15 mg/kg/d) [12]; specifically those attaining well-defined 
biochemical response criteria in whom survival parallels that of an age and sex-matched control 
population [13–20]. However, therapeutic failure is evident in up to 40% of PBC patients 
[13,14], with biochemical non-response independently associated with disease progression, liver 
transplantation (LT) and death, highlighting a critical need for alternative / adjuvant pharmaco-
intervention. 
 
Farnesoid X receptor (FXR) is a nuclear ‘ligand-activated’ receptor abundantly expressed in 
tissues that engage in the enterohepatic circulation of bile acids. However, unlike UDCA which 
operates at a post-translational level, FXR-signalling directly regulates genes involved in bile 
acid synthesis, secretion, transportation, absorption and detoxification [21]. Chenodeoxycholic 
acid (CDCA) and its semi-synthetic analogue obeticholic acid (OCA) are selective ligands for 
FXR, with the latter illustrating exponential activation potency relative to its endogenous 
counterpart (Figure 1) [22]. OCA also induces expression of fibroblast growth factor (FGF)-19, 
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which could plausibly explain the puissant anti-inflammatory and portal hypotensive effects 
observed in several experimental models [23–25]. Moreover, the clinical impact of FXR-
agonism has recently been explored through phase II and phase III trials of OCA in PBC, which 
demonstrate significant improvement in validated biochemical surrogates of disease outcome 
[26]. Herein, we present a synthesis of the available experimental and clinical evidence that have 
driven emergence of OCA as a viable therapeutic option for PBC patients. 
 
Natural history of PBC 
Primary biliary cirrhosis is the most common of all autoimmune hepatobiliary diseases, with an 
estimated prevalence of 1 per-1000 in women over the age of 40 [27,28]. Diagnosis is reliant 
upon features of chronic biochemical cholestasis, circulating disease-specific anti-mitochondrial 
antibodies (AMA; present in >90% of patients), and/or or characteristic biopsy findings of 
destructive non-suppurative granulomatous/lymphocytic cholangitis [29]. Pruritus and fatigue 
represent the archetypal symptoms in chronic cholestasis and need not necessarily relate to liver 
disease severity, nor abate with UDCA therapy [30]. Although non-specific, both significantly 
impact quality of life and represent a significant unmet need [31].  
 
The classical ‘textbook’ presentation of PBC implies disease restriction to middle-aged, often 
post-menopausal women with a median survival of approximately 9 – 10 years from presentation 
[32,33]. Advanced histological stage is a clear determinant of poor clinical outcome and in an era 
where liver biopsy was the norm and effective therapy lacking, the median time to develop 
extensive fibrosis was ~2 years and probability of remaining in early stage disease <30% over a 
4-year period [34,35]. However, the advent of high-accuracy AMA testing largely obviates 
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 5
routine, diagnostic histological assessment [27,36], and PBC is increasingly identified at an 
earlier, pre-cirrhotic stage with progressive recognition of male patients and young women of 
child-bearing age [14,37–39]. Approximately 60% of patients with PBC are asymptomatic at 
time of diagnosis, however as little as 5% remain symptom-free over time [33]. Furthermore, it is 
now apparent that presenting age and gender influence the presenting phenotype, with young 
women – a group who fail UDCA therapy more commonly – having the greatest symptom 
burden.  
 
Ursodeoxycholic acid is currently the only approved drug for treating PBC, demonstrating 
consistent evidence in improving liver biochemistry [40,41] and a lower progression rate from 
early stage disease to extensive fibrosis/cirrhosis compared with placebo in clinical trials (7% vs. 
35% per-year; p<0.01) [42]. Observed 10-year transplant-free survival indices are significantly 
better in UDCA-treated patients (78% vs. 59%; p<0.001 [38]) however remain lower than age- 
and sex-matched control populations in the current era [13,14,43].  
 
On-treatment liver biochemical changes are variable in PBC, with some patients experiencing 
complete normalisation and others only minor improvements. Serum bilirubin is well-established 
as an independent predictor of prognosis, regardless of treatment, although is limited to 
prediction of short-term survival (<2 years) during relatively late-stage disease [44]. A 
relationship between ALP and risk of adverse outcomes has been extensively documented across 
several studies; however, it was only recently that a systematic, international multi-centre study 
validated worth as a biochemical surrogate by demonstrating a near log-linear relationship 
between serum ALP and risk of transplantation/death across several time points [38]. Serum 
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ALP bestows incremental prognostic information to bilirubin alone; an association independent 
of patient follow-up time that holds true irrespective of presenting age, sex, disease stage and 
treatment status. To this effect, several studies illustrate a strong association between 
normalisation, percentage reductions or absolute decreases in serum ALP (either in isolation, or 
in association with other biochemical covariates) and improved transplant-free survival on 
UDCA-therapy [13–15,17]. Conversely, biochemical ‘non-responders’ exhibiting persistent 
elevations in serum ALP represent the current target population for evaluation of new therapies 
in PBC. 
 
PBC as a cholestatic disease 
Understandings of PBC disease pathophysiology are incomplete; with initiation of immune-
mediated small bile duct cholangitis likely reflecting strong genetic risk coupled with 
environmental induction [2,45–47]. Ductopenia is propagated by a multi-lineage humoral and 
cellular adaptive response, but may also include innate immune reactions against cholangiocytes. 
The autoimmune nature of PBC is characterised by a distinct loss of tolerance to a series of 
mitochondrial autoantigens and integrally related to bile duct loss, which progresses through an 
iterative inflammatory process from lymphocytic cholangitis to progressive ductopenia, 
associated cholestasis and eventually biliary fibrosis [2]. OCA is an agent that predominantly has 
an impact on cholestasis; hence immune aspects of PBC are not discussed further. 
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An overview of bile secretion  
Conjugated bile acids are the major component of bile, and transported across the basolateral 
hepatocyte membrane by the sodium taurocholate co-transporting polypeptide (NTCP; or solute 
carrier family 10 member 1, SLC10A1); whereas unconjugated bile acids and a large variety of 
other organic anions (including bilirubin) are taken up from the circulation via a series of organic 
anion transporters (OATP) [48]. The canalicular secretion of bile acids is facilitated by a number 
of adenosine triphosphate binding cassette (ABC)-transporters, with passage specifically 
dependent upon the bile salt export pump (BSEP; or ABC11). A further ABC transporter, the 
multi-drug resistance 3 P-glycoprotein (MDR3; or ABCB4) is also required for biliary secretion 
of phosphatidylcholine which facilitates packaging of bile as mixed micelles, therein protecting 
biliary epithelium from oxidative injury [48]. In addition, cholangiocytes secrete an alkaline-rich 
fluid, with the cystic fibrosis transmembrane conductance regulator (CFTR; or ABCC7) 
responsible for the efflux of chloride that is subsequently exchanged against bicarbonate via the 
anion exchanger 2 (AE2; SLC4A2). The resultant ‘bicarbonate umbrella’ serves to maintain an 
alkaline pH near the apical surface of hepatocytes and cholangiocytes to prevent uncontrolled 
membrane permeation by protonated, glycine-conjugated bile acids [49]. This protective 
mechanism is also reliant on an intact biliary glycocalyx on human cholangiocytes, and 
dysregulation or functional impairment of the biliary bicarbonate umbrella may lead to enhanced 
vulnerability of cholangiocytes and peri-portal hepatocytes towards hydrophobic bile acids.  
 
The basolateral hepatocyte membrane possesses a number of additional transporters that are 
normally expressed at very low levels, but compensatory up-regulated in cholestasis. These 
include multidrug resistance-associated protein 4 (MRP4; or ABCC4) which transports bile acids 
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together with glutathione, MRP3 (or ABCC3) which transports conjugated bilirubin and other 
organic anions, and the organic solute transporter (OSTα/OSTβ) that transports bile acids and 
sterols [50]. Reduced immunostaining of the chloride-bicarbonate anion exchanger AE2 and 
other ion-exchange pumps have been demonstrated in the PBC liver [51], which fail to respond 
to adenosine triphosphate stimulation with secretin; and their ability to dilute and alkalinize 
canalicular bile upon stimulation lost in untreated disease, but restored in patients receiving 
UDCA [52]. Conjugates of UDCA have also been shown to activate vesicular exocytosis and 
carrier insertion into the apical membrane of hepatocytes and cholangiocytes, resulting in 
additional choleresis via MAPK- and α5β1 integrin-dependent mechanisms. Anti-cholestatic 
effects of UDCA are predominantly dependent on Ca
2+
-dependent signalling (inositol-
triphosphate receptor and protein kinase), with well-known anti-apoptotic functions conferring 
additional hepatoprotective and cholangioprotective benefit [53,54].  
 
The expression of certain other hepatocellular transporter genes may also vary depending on 
disease stage [55]. Early reports indicate activity of hepatic cholesterol 7 alpha-hydroxylase 
(CYP7A)-1 – the rate-limiting enzyme involved in bile acid synthesis – as significantly increased 
in early PBC, but reduced to levels 10 – 20 % of that found in normal controls as the condition 
progresses [55,56]. Down-regulation of OATP2 and increased mRNA expression of NTCP and 
BSEP have also been reported in late-stage disease and likely represent protective mechanisms 
that have evolved to prevent accumulation of toxic bile acids. Nuclear hormone receptors 
regulate such adaptive responses, and include the pregnane X receptor (PXR), the constitutive 
androstane receptor (CAR) and the peroxisome-proliferator-activator receptor α (PPARα) [21], 
with FXR representing the key sensor involved in bile acid feedback regulation [57]. In contrast 
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 9
to hydrophobic bile acids such as CDCA or lithocholic acid (LCA), UDCA does not markedly 
affect transport protein expression at the transcriptional level, and has limited effect on post-
transcriptional carrier modification [58]. 
 
The farnesoid X receptor 
FXR is predominantly expressed in the liver and small intestine, with highest levels observed at 
the terminal ileum. Upon ligand binding within the liver, FXR suppresses transcription of 
CYP7A1 via the target gene short heterodimer protein (SHP); as well as promoting canalicular 
bile salt secretion through up-regulation of BSEP and MDR3 and alternative routes of bile acid 
elimination such as OSTα/OSTβ [59,60]. In addition, ileal FXR ligation up-regulates expression 
of FGF19 that upon entry into the portal circulation binds to the receptor FGFR4 on hepatocytes. 
This in turn activates a series of MAP-kinases which further suppress CYP7A1 expression 
synergistically with SHP [61], as well as exerting potent pro-glycogenic and anti-lipogeneic 
effects (Table 1) (Figure 2). These findings have been successfully translated into clinical trials 
for non-alcoholic fatty liver disease (NAFLD) [62,63]. 
 
Although FXR response elements exist in the proximal region of the human MDR3 promoter 
(MDR3 mRNA levels increasing following FXR ligation [64]), Fxr knockout mice still respond 
to a cholic acid rich diet with an increase in transcription of Mdr2 (the murine orthologue of 
MDR3 [65]). Indeed, activation of the nuclear hormone receptor PPARα by its synthetic ligand 
Fenofibrate enhances MDR3 mRNA and protein expression on primary human hepatocytes to a 
greater degree than CDCA, although a synergistic effect is not observed [66]. Moreover, ligand 
activated PPAR can attenuate bile acid synthesis (through direct inhibition of CYP7A1 and 
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CYP27A1), regulate bile acid detoxification (increased hepatic glucoronidation activity) and 
stimulate biliary excretion of phosphatidylcholine (enhanced MDR3 expression) [67]; suggesting 
that FXR-mediated effects may also be exerted indirectly via PPARα activation. 
 
Pre-clinical models targeting FXR 
The critical role of FXR in curbing BA synthesis can be illustrated in Fxr knockout mice, which 
exhibit an increased bile acid pool size and phenotypic features akin to the human condition 
progressive familial intrahepatic cholestasis [65,68]. These models illustrate a prominent role for 
intestinal FGF15 signalling (murine orthologue of FGF19) over SHP in the repression of 
CYP7A1 activity [69]. By contrast, constitutive FXR activation in the intestine has been shown 
to protect against chemical and obstructive cholestasis in at least two murine models [70]. 
Further anti-cholestatic effects are evident following systemic pharmacologic activation of FXR 
in rats, which exhibit decreased expression of bile acid biosynthetic genes and up-regulation of 
those involved in bile acid transport [71]. More incipient studies have suggested that effective 
bile acid signalling plays a critical role in liver regeneration [72]; and in an elegant series of 
experiments using humanised mouse livers, Naugler et al. illustrated that FGF19-signalling was 
able to increase hepatocyte proliferative responses in a murine model of PBC [24]. Of further 
interest was the observation that FGF19 transcription although virtually absent from normal 
healthy liver in man, was readily detected in sorted cholangiocytes from PBC liver, suggesting 
the existence of more local regulatory networks in chronic cholestasis. 
 
Liver natural killer T-cells may also express functional FXR, and regulatory functions are 
suggested by mouse models in which congenital Fxr deletion confers enhanced susceptibility to 
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T-cell-mediated hepatitis (an effect likely mediated through NFκB-signalling), increased 
expression of pro-inflammatory cytokines and oncogenes, and spontaneous development of 
hepatic tumours [73–76].  
 
Pre-clinical data also indicates that FXR is expressed by rat hepatic stellate cells (HSC) which 
are the precursors of hepatic myofibroblasts (MFB) – key drivers of hepatic fibrogenesis [77–
79]. Indeed, FXR activation was associated with reduced secretion of extra-cellular matrix 
(ECM) as well as prevention and resolution of liver fibrosis in carbon-tetrachloride (CCl4) and 
bile-duct ligated (BDL) rats [77]. These findings have not, however, been recapitulated in all 
murine studies; and Fickert et al. report cell-type specific expression of FXR as relatively low in 
mouse as well as human HSC and hepatic MFB compared to that observed in whole liver [80]. 
Nevertheless, Fxr loss significantly attenuated liver fibrosis specifically in models of biliary 
(BDL, or dietary 3,5-diethoxycarbonyl-1,4-dihydrocollidine application), but not parenchymal 
liver disease (Schistosoma mansoni infection, or CCl4).  
 
FXR agonism has also been shown to reduce portal hypertension in vivo through a direct action 
on endothelial nitric oxide synthase (eNOS) activation, inhibition of endothelin-1 mediated HSC 
contraction, and consequently a reduction in intra-hepatic vascular resistance [25,81]. This 
observation is of particular relevance in the risk reduction profile of PBC, given the negative 
prognostic implications of portal hypertensive disease on clinical outcomes [18,82,83]. 
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Obeticholic acid – development for PBC 
CDCA and cholic acid (CA) are the natural ligands for FXR. Shortly following identification of 
the latter, OCA was generated as the ‘first-in-class’ synthetic agonist, which incorporates a 6α 
ethyl substitution to CDCA (synonymously known as 6-ECDCA). This modification endows 
OCA with >100-fold activating potency as evident in cell-free ligand sensing as well as reporter 
gene assays, relative to all previously identified bile acids [22]. Moreover, in a rat model of 
lithocholic acid induced cholestasis, OCA (5–30mg/kg) significantly improved bile flow and 
hepatocellular injury; however, the in vivo effects were short-lived. In keeping with FXR 
agonistic effects, significant increases in FGF19 were observed following OCA provision as part 
of assessment in a recent Phase-II clinical trial [26]. These changes were paralleled by reductions 
in 7α-hydroxy-4-cholesten-3-one (C4) as a precursor of bile acid synthesis, in addition to lower 
total circulating bile acid concentrations.  
 
OCA is rapidly absorbed and extensively conjugated to the amino acids glycine and taurine. The 
conjugates are near equipotent on the FXR receptor and undergo enterohepatic recirculation akin 
to CDCA, making estimation of drug half-life somewhat difficult (no data available at time of 
writing). Pharmacokinetic characteristics are also broadly similar, with the exception of the 7-
dehydroxylation step being restricted to CDCA [84].  
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Phase II / III clinical trials 
Clinical outcomes in PBC are largely dictated by development of cirrhosis and portal 
hypertensive complications; however, the slowly progressive nature effectively precludes 
evaluation of classical endpoints such as hepatic decompensation or transplant-free survival in 
clinical trials. Histological assessment although a robust indicator of disease progression in liver 
disease, is not ideal given its invasiveness and well-known sampling variability in chronic 
cholestasis. These barriers have fostered the development of several plausible surrogates, of 
which serum ALP is validated as most secure in predicting long-term outcome [38].  
 
Results from the first randomised, double-blind controlled trial in PBC were recently published, 
wherein the therapeutic efficacy of UDCA and three doses of OCA (10, 25, and 50 mg/d) 
compared against UDCA/placebo [26]. Entry into this internationally representative trial was 
restricted to patients exhibiting persistent elevations in serum ALP >1.5 times the upper limit of 
normal (ULN) whilst on a stable dose of UDCA for at least 6 months. The primary endpoint 
herein was a significant reduction in serum ALP from baseline, and met across all three doses of 
OCA versus placebo (Table 2). Moreover, 87%, 69% and 7% of all OCA-treated patients 
completing therapy achieved a decline in serum ALP of at least 10%, 20% or complete 
normalization (vs. 14%, 8% and 0% with placebo). Statistical differences in absolute ALP 
reductions were also evident in all OCA-treated patients, with attainment rates of established 
PBC biochemical response criteria being significantly greater in the 25 mg/d group at end of trial 
[26]. Another phase II study adopted similar inclusion criteria but evaluated OCA monotherapy 
(10 and 50 mg) versus placebo in the absence of concomitant UDCA provision [85]. Statistically 
significant relative and absolute reductions in ALP were reported for both doses of OCA versus 
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placebo (from baseline: –233.5 IU/L and –161 IU/L vs. +12 IU/L; p<0.0001), as well as 
improvements in serum bilirubin. Results from this trial await formal reporting and currently 
available data is restricted to abstract form. 
 
Preliminary data from the only phase III study of OCA (PBC OCA International Study of 
Efficacy; POISE) have also recently been presented [86] [submitted; under review]. Akin to its 
predecessors the POISE study recruited PBC patients with persistent elevation in serum ALP 
(prior biochemical non-response according to Toronto criterion) but also those intolerant to 
UDCA. The primary endpoint during the 12-month double-blind period was attainment of both 
an ALP level <1.67 × ULN (with a ≥15% reduction from baseline) and a normal serum bilirubin. 
Patients were randomised to receive either placebo, 10 mg OCA, or 5 mg OCA for 6 months 
titrated to 10 mg OCA based on clinical response; and pre-existing UDCA therapy was 
continued at a stable dose (7% UDCA intolerant). All test groups were well-matched and in an 
intention-to-treat analysis response was met in 10% of the placebo group relative to 47% and 
46% in the 10 mg and dose-titrated OCA groups, respectively (p<0.0001 for both; Figure 3). The 
mean decrease in ALP from baseline was 39 % and 33 % in the 10 mg and titrated OCA-groups, 
respectively, versus 5% for patients in receipt of placebo (p<0.0001 for both). In addition, both 
OCA groups met pre-defined secondary endpoints including reduction in serum AST and total 
serum bilirubin (both OCA groups p<0.001 vs. placebo).  
 
The encouraging results from phase II and phase III studies represent a significant milestone in 
PBC; however, longer-term efficacy of obeticholic acid (OCA) and generalizability to the patient 
population as a whole need confirmation in prospective follow-up studies. This is of particular 
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importance given the limited number of patients enrolled in aforementioned clinical trials – a 
reflection of the relative infrequency of PBC globally [87]. Up till now enrolment into clinical 
trials has been restricted to individuals demonstrating persistent elevations in serum ALP, with 
therapeutic efficacy gauged through percentage change or absolute decline. It is plausible 
therefore, that the beneficial effect of OCA (and other novel bile acid therapies) will be restricted 
to patients failing to achieve biochemical response based on ALP criteria. However, there is no 
currently available data regarding therapeutic efficacy stratified according to the magnitude of 
serum ALP elevations at point of trial inclusion. Assessment of further surrogates of clinical 
outcome (including for instance AST/platelet ratio, liver stiffness measurements derived via 
transient elastography) would be of additional clinical benefit in this regard [18,88]. 
 
Safety and tolerability 
The favourable changes observed in serum liver biochemistry were mirrored by significant 
reduction in circulating immunoglobulin levels and serum inflammatory markers (Figure 4); 
which although not directly linked with prognosis, suggests mediation of underlying 
immunological and inflammatory processes driving disease pathogenesis [26]. However, 
treatment with OCA is not without concern. Pruritus was a major side effect in the clinical trials, 
leading to treatment discontinuation in >10% of subjects in phase II studies (Figure 5a) [26]. 
Moreover, in the open-label long-term safety extension phase (n=78, 12 months – 61 patients 
completed) ALP reductions were sustained in all of the completer population, yet 87% reported 
pruritus at some point with ~10% overall needing to discontinue therapy. OCA-induced pruritus 
appears to be a dose-dependent effect and in the phase III clinical study was addressed (in part) 
through the dose-titration arm (Figure 5b) and provision of colestyramine (proportion of patients 
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receiving colestyramine: 11%, 19% and 26%; in the placebo, dose-titration and 10mg arms, 
respectively). However, it is unclear whether attenuation in itch severity over time (10mg group) 
was specifically due to symptom-specific intervention or due to development of OCA-tolerance, 
and data pertaining to colestyramine initiation date/duration is currently unavailable [63]. In 
addition to being a selective ligand for FXR, OCA may act as a partial agonist for 
transmembrane G-protein-coupled receptor (TGR)-5 – a receptor widely distributed in brown 
adipose tissue, skeletal myocytes, Kupffer cells, cholangiocytes, and enteroendocrine cells within 
the intestine [21,89]. More recently, TGR5 transcriptive signals were identified in cutaneous 
afferent neurons wherein direct bile acid stimulation was able to induce pruritus in mice [90,91], 
with receptor overexpression associated with enhanced basal scratch activity. In support of the 
TGR-5 hypothesis of cholestatic pruritus, intradermal injection of the bile-salt deoxycholate (a 
TGR5 agonist) has been shown to induce scratch activity in wild type mice; however, this was 
only partially attenuated in animals harboring a congenital Tgr5 deletion suggesting additional 
pathogenic mechanisms. Bile salts may also lead to activation and degranulation of mast cells 
[92], although a wealth of research effort has failed to illustrate causal relationships between 
pruritus and either serum bile salt concentration or histaminergic activity [93]. Moreover, 
antihistamines have historically proven ineffective in the treatment of cholestatic pruritus.  
 
PBC patients with early disease have elevated total lipid levels although risks of cardiovascular 
morbidity do not appear disparate relative to the general population [94]. Changes in serum 
lipids were observed in trials of OCA; specifically, a decrease in high-density lipoprotein (HDL) 
as early as 2 weeks of treatment coupled with an increase in total and LDL cholesterol (levels 
returned to baseline within 2 weeks of treatment cessation). One possible explanation is that by 
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attenuating hepatic bile acid synthesis cholesterol elimination is consequently reduced. Lipid 
effects in animals relate to up-regulation of reverse cholesterol transport, wherein Fxr knockout 
mice exhibit hypercholesterolemia. However, in this instance lipid changes reflect marked 
elevation in HDL levels secondary to down-regulation of scavenger receptor class B member 1 
(SCARB)-1 – a receptor for hepatic clearance of cholesterol from HDL [65]. Indeed, OCA has 
been shown in animal models to lower atherogenic plaque formation via selective reduction of 
HDL2c or ApoAI [95,96]. Of interest, lipophilic bile acids which bind to FXR have been shown 
to promote insulin sensitivity and decrease hepatic gluconeogenesis and circulating triglyceride 
levels, ostensibly mediated by decreased lipid synthesis within the liver and enhanced peripheral 
clearance of VLDL, in addition to SCARB-1–mediated actions [97–100]. Based on these 
metabolic effects, OCA has also been proposed as a target for the treatment of NASH [62,63]; 
however, dedicated studies in PBC are needed to specifically delineate the vascular implications 
stemming from current findings. 
 
Expert Commentary and 5 Year View 
The FXR axis is the most dedicated of all signalling pathways that mediate bile acid 
homeostasis. Proven beneficial effects of receptor ligation and/or functional overexpression 
encompass choleresis, anti-inflammatory and anti-fibrotic properties, as well as tissue 
regeneration in pre-clinical models. Presently, OCA represents the most powerful of all 
(clinically-trialed) FXR agonists, and results from randomized trials are supportive of therapeutic 
merit in PBC, at least gauged by non-invasive yet highly validated and robust clinical outcome 
predictors. Biochemical efficacy is apparent across all currently tested dosages (5 mg – 50 mg) 
which given the dose-dependent effect on pruritus explains the use of lower-dose regimens in the 
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Phase III trial. Longer-term safety and durability monitoring is of importance in view of the 
persistently elevated FGF19 titres in OCA-treated patients. The role of FXR/FGF19 in cancer 
development is complex, with both protective and deleterious concerns. For instance, HCC 
develops spontaneously in aged Fxr null mice, but can be prevented by re-expressing a 
constitutively active form of FXR in the intestine [101]. Conversely FGF19 transgenic mice are 
seen to develop spontaneous hepatocellular carcinoma (HCC) [102], and FGF19 amplifications 
have been implicated in driving hepatic carcinogenesis in man [103,104]. Given the positive 
effects on hepatocyte proliferation, such oncogenic properties are likely a consequence of 
supraphysiological circulating FGF19 levels and support the need for appropriate safety 
monitoring of drugs modulating the FXR axis, particularly as biochemical non-responders in 
PBC represent a group in which HCC-risk is greatest [105]. Of interest, the ostensible mitogenic 
effects of FGF19 can be abrogated through substitution of a 7-amino acid region that comprises 
an FGFR4-interaction domain [106], and is of particular relevance for emerging FGF19 agonists. 
 
The role of FXR/FGF19 in cancer development is complex, with both protective and deleterious 
concerns. For instance, development of HCC in aged Fxr null mice can be prevented by re-
expressing a constitutive active form of FXR in the intestine [101]; conversely FGF19 transgenic 
mice are seen to develop spontaneous hepatocellular carcinoma (HCC) [102], and FGF19 
amplifications have been implicated in driving hepatic carcinogenesis in man [104]. These 
discrepant findings support the need for appropriate safety monitoring of drugs that modulate the 
FXR axis; particularly given that biochemical non-responders in PBC represent a group in which 
HCC-risk is greatest [105]. 
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The requirement for additional medical treatment in PBC is clearly recognized; and in addition to 
OCA, synthetic agonists of PPAR are perhaps furthest in terms of clinical study. To this effect, 
several non-controlled studies report an improvement in serum ALP following administration of 
Fenofibrate in addition to UDCA (mean decrease from a recent meta-analysis of 6 case series: 
114 IU/L [107]). Similar results have also been garnered with regard to Bezafibrate (PPARα/δ/γ 
agonist), which has the added benefit of alleviating pruritus of cholestasis [108,109]. 
Unfortunately, many studies of fibrates are limited in terms of patient number follow-up (some 
<8 weeks in duration), lack of appropriate controls, application of sub-optimal UDCA dosages 
and ill-defined patient populations (biochemical response not consistently defined). Moreover, 
fibrates have been associated with development of renal dysfunction; and long-term efficacy and 
safety data eagerly awaited. A phase III randomized control trial of Bezafibrate in PBC is 
currently underway. 
 
Further avenues for therapeutic development in PBC include targeting additional nuclear bile 
acid receptors (e.g. TGR5, PXR, CAR), immunomodulatory therapies (e.g. targeting pathways 
such as CD40, CTLA-4, CD80, JAK-STAT signaling), and cell-based therapies (mesenchymal 
stromal cells) are in development, all alongside drugs that modulate FXR function (INT-767; a 
dual FXR/TGR5 agonist with greater FXR-activating potency than OCA), or change bile acid re-
circulation (ASBT-inhibitors)/biliary function (norUDCA). A detailed discussion pertaining to 
each of these approaches is beyond the scope of this review, and covered elsewhere [7,110–116].  
 
To apply OCA and other therapies there remains a need to better understand the underlying 
pathogenesis of disease so that drugs target the predominant immunologic, metabolic and fibrotic 
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components to achieve best prevention and treatment of progressive disease. With an increasing 
understanding of the effector mechanisms that lead to biliary destruction, a major focus should 
take advantage of basic science observations so that they can be transferred to viable therapeutic 
tools, much like that which has occurred in rheumatoid arthritis and inflammatory bowel disease 
[117–120]. We would emphasize that such efforts will need to take advantage of newer 
technologies involving pathway analysis, microRNA, high throughput assays, gene replacement 
and dissection of the microbiome [7,121].  
 
In conclusion there is clearly a significant unmet need for new therapies in patients with 
cholestatic liver diseases [110–113]. Thus, as well as its development programme in non-
alcoholic steatohepatitis; OCA, a selective FXR agonist, represents one new potential treatment 
on the horizon for patients with PBC.  
 
Key Issues: 
 
• Primary biliary cirrhosis (PBC) is a chronic autoimmune liver disease in which clinical 
course is characterized by cholestasis, and outcome dictated by development of cirrhosis and 
portal hypertension.  
• Presently, ursodeoxycholic acid (UDCA) is the only licensed medical treatment; and for 
those who meet specific biochemical response criteria (60 – 70% of all patients), clinical 
outcome is excellent.  
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• However, therapeutic shortfall of UDCA is evident in approximately one-third of the PBC 
population, particularly those failing to attain biochemical response, who experience 
progressive liver disease despite adequate UDCA provision. 
• Obeticholic acid (OCA) is a semi-synthetic analogue of chenodeoxycholic acid that 
demonstrates potent anti-cholestatic, anti-inflammatory, anti-fibrotic and cell-proliferative 
effects in pre-clinical models of hepatobiliary injury, mediated through activation of the 
nuclear farnesoid X receptor (FXR).  
• In phase II and phase III PBC clinical trials, OCA (monotherapy, or in addition to UDCA) 
resulted in significantly greater improvement to proven biochemical surrogates of clinical 
outcome, relative to placebo (+ UDCA). 
• Pruritus is the most significant side effect of OCA treatment, although this can be overcome 
through appropriate dosage titration and provision of bile acid sequestrants.  
• Longer-term studies are needed to explore safety concerns and validate clinical efficacy.  
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Table 1: Pleiotropic effects of FXR signaling [21] 
Natural ligands and potency Actions Target tissues 
CDCA > DCA > LCA > CA Up-regulated pathways 
- Bile acid export 
- Tumor suppression 
- Hepatic regeneration 
- Phase I/II drug metabolism 
- Intestinal barrier function 
Down-regulated pathways 
- Bile acid synthesis 
- Hepatic inflammation 
- Lipogenesis 
- Gluconeogenesis 
- ECM production and tissue 
fibrosis 
Liver 
Intestine 
Kidney 
CDCA: Chenodeoxycholic acid, DCA: deoxycholic acid, LCA: lithocholic acid, CA: cholic acid, ECM: 
extracellular matrix 
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Table 2: Randomized, Double-Blind Placebo Controlled Trials of Obeticholic Acid in Primary Biliary Cirrhosis 
Study phase *  OCA dose No. Participants  1
o
 Endpoint Met  
II [26] 
1
 o
 endpoint: % reduction in serum ALP 
Duration: 12 weeks 
Inclusion: ALP >1.5 x ULN + <10 x ULN 
 165; 136 completed Mean % ALP decrease ** 
Placebo 38 3% 
10 mg 38 34%  
25 mg 48 25% 
50 mg 41 21% 
II [85] – OCA monotherapy vs. placebo  
1
 o
 endpoint: % reduction in serum ALP 
Duration: 12 weeks 
Inclusion: ALP >1.5 x ULN and no UDCA >6 mo. 
 59 *** Mean % ALP decrease ** 
Placebo 23  N/A (+0.4%) 
10 mg 20  45% 
50 mg 16  38% 
III [86] 
1
o 
endpoint: serum ALP <1.67 × ULN (with ≥15 % reduction from 
baseline) and normalization of bilirubin  
Duration: 12 months 
Inclusion: ALP ≥1.67 x ULN and/or total bilirubin >ULN to <2 x ULN 
 216; 198 completed Attainment rate ** 
Placebo 73 10% 
10 mg 70 47% 
10 mg to 50 mg;  
- dose titration at 6 months 
73 46% 
* All studies included patients on a stable dosage of UDCA for > 6 months except that by Kowdley et al. 
** Indicate statistically significant differences  
*** Completer population figures not available at time of writing 
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Figure Legends 
Figure 1: Obeticholic acid structural characteristics 
Obeticholic acid is a synthetic analogue to the endogenous farnesoid-X-receptor (FXR) ligand 
chenodeoxycholic acid (CDCA), albeit with >2 log potency as regards to receptor activation, as 
illustrated by the half maximal effective concentration (EC50). By contrast, the CDCA epimer 
ursodeoxycholic acid (UDCA) does not harbour any FXR agonistic effects. 
 
Figure 2: FXR agonism and bile acid homeostasis 
Bile acids (BA) are synthesis by hepatocytes via cholesterol 7 alpha-hydroxylase (CYP7A1)-
mediated conversion of cholesterol. Bile salts are secreted via the bile salt export pump (BSEP) 
into canaliculi for subsequent transport to the gut. Reclamation of bile salts occurs via the apical 
sodium bile acid transporter (ASBT) on ileal enterocytes, and facilitates activation of FXR and 
transcription of fibroblast growth factor (FGF)-19. The latter is subsequently transported to the 
liver via the portal circulation where ligation of its cognate receptor (FGFR4) initiates a cascade 
of intracellular signals that suppress CYP7A1 expression and consequently BA synthesis. Bile 
acids can also be shuttled from enterocytes to the liver via organic solute transporters (OST), and 
taken up by the sodium-taurocholate transporter (NTCP). In the liver, bile acids bind hepatic 
FXR, which in turn up-regulates small heterodimer (SHP) as another repressive mechanism of 
CYP7A1 transcription. FXR agonists such as obeticholic acid (OCA) exert their functional 
effects in the liver and gut, to a greater degree than natural ligands in a fervent effort to down-
regulate CYP7A1 expression. FXR agonists may also mediate bile salt excretion via up-
regulation of BSEP, and provide additional protective effects through up-regulation of the 
flippase multidrug resistance protein 3 (MDR3). 
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Figure 3: Attainment of primary and secondary endpoints in the POISE study. 
The primary endpoint in the obeticholic acid (OCA) phase III trial in PBC was biochemical 
response at the end of treatment (12 months; response defined as: ALP < 1.67 x ULN and >15 
decline from baseline; and normal serum bilirubin) phase (A). Percentage reductions in serum 
ALP (B) and fluctuations in bilirubin (C) as well as AST (D) are also presented for comparison. 
Statistically significant differences are indication by asterisks (*p<0.001 vs. placebo) [86]. 
 
Figure 4: Immunoglobulin and pro-inflammatory cytokine profiles  
Provision of obeticholic acid (OCA) led to reduction in circulating immunoglobulin levels (A), 
as well as notable fluctuations in the serum concentration of pro-inflammatory cytokines (B). 
Data is presented for the phase III study only. Statistically significant differences are indication 
by asterisks (*p<0.05, **p<0.01, **p<0.001 vs. placebo) [86]. 
 
Figure 5: Pruritus and obeticholic acid in primary biliary cirrhosis 
The most common side effect of obeticholic acid (OCA) therapy is (dose-dependent) pruritus. 
Summary data is shown for the phase II trial of OCA-monotherapy (A), wherein bar height 
indicates overall incidence of symptoms, and orange box the proportional discontinuation rate 
[85]. Similar rates were manifest in the phase II trial of OCA + ursodeoxycholic acid (UDCA) 
and have been presented elsewhere [26]. The phase III study incorporated a dose titration step in 
an effort to minimise severity of pruritus (B), with 8 patients overall discontinuing therapy due to 
refractory symptoms (none in the placebo group, n=7 in the 10mg group and n=1 in the titration 
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group; data not shown). Statistically significant differences are indication by asterisks 
(*p<0.0001 vs. placebo) [86]. 
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